Aurinia Acquires Novel Pipeline Assets Targeting Autoimmune and Kidney-related Diseases
- Assets expand immunology portfolio to include B-cell therapy (BAFF/APRIL) and macrophage modulation -
- IND-enabling studies are ongoing and will support the transition of these assets to clinical development in 2022/2023 -
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company) today announced the addition of two novel assets that will expand the Company's rare autoimmune and kidney-related disease pipeline.
"Over the past year, in anticipation of building out and diversifying our development pipeline, we have brought on additional large and small molecule expertise that uniquely aligns with Aurinia's focus on immunology and nephrology," said Peter Greenleaf, President and
